

Reference:	FOI.4736.20
Subject:	Antiretroviral therapies
Date of Request:	10 December 2020

Requested:

1. How many patients were treated (for any condition) in the latest 6-month period with the following drugs:
 - Juluca (rilpivirine/dolutegravir)
 - Dovato (lamivudine/dolutegravir)
 - Triumeq (abacavir/lamivudine/dolutegravir)
 - Tivicay (dolutegravir)
 - Isentress (raltegravir)
 - Biktarvy (TAF/emtricitabine/bictegravir)
 - Genvoya (TAF/emtricitabine/elvitegravir/cobisistat)
 - Symtuza (TAF/emtricitabine/darunavir/cobisistat)
 - Odefsey (TAF/emtricitabine/rilpivirine)
 - Descovy (TAF/emtricitabine)
 - Truvada or generic TDF/emtricitabine
2. How many patients received any antiretroviral (ART) therapy for HIV treatment (excluding pre-exposure prophylaxis):
 - for the latest 6-month period
 - for the 6 months from July-December 2019
3. How many patients were treated in the latest 6-months period with Truvada or generic TDF/emtricitabine for:
 - HIV treatment
 - Pre-exposure prophylaxis (PrEP)
4. How many packs of Truvada or generic TDF/emtricitabine were dispensed in latest 6-month period for:
 - HIV treatment
 - Pre-exposure prophylaxis (PrEP)

Response:

Hywel Dda University Health Board (UB) regrets to inform you that it does not hold the information requested in relation to HIV.

HIV treatment is provided by Swansea Bay University Health Board (SBUHB). We would therefore recommend that you redirect your requests relating to HIV to the Freedom of Information Team in SBUHB who may be able to help you with your enquiry:

FOIA.Requests@wales.nhs.uk or alternatively, you can contact: FOIA Team, Swansea Bay University Health Board, Health Board Headquarters, 1 Talbot Gateway, Port Talbot, SA12 7BR.

Whilst operating in accordance with the Chancellor's Code of Practice under Section 45 of the Freedom of Information Act 2000, the UHB has a duty to provide advice and assistance, therefore, the UHB provides the information it does hold below.

1. The UHB confirms that it has dispensed nineteen (19) Truvada prescriptions, for all conditions, during the requested period.
3. The UHB confirms that there are approximately fifty (50) patients currently receiving the medication Truvada. During 2020, Pre-Exposure Prophylaxis (PrEP) treatment was withdrawn due to the pandemic as per the restrictions imposed within the local and national COVID-19 policies. However, PrEP treatment recommenced 3 December 2020.
4. The UHB confirms that one hundred and fifty four (154) packs of thirty (30) Truvada tablets were dispensed, including five (5) packs issued as stock for PrEP with five (5) packs of Raltegravir, during the requested period.

Please note, that the UHB can only provide the number of medications dispensed and not the number of medications issued to patients.